eClinical Solutions, a global provider of cloud-based enterprise software and software-driven clinical data services, has revealed a more than 40% annual license growth of its elluminate Clinical Data Platform in 2020. This brings the total global adoption of elluminate to over 100 life sciences companies.
elluminate helps life sciences companies manage the increasing volume and diversity now available in clinical research including data streams from decentralized trials. By unifying diverse, disparate data sources into one centralised platform for real-time access, standardisation and analysis, elluminate is designed to helps organisations optimise the value of their clinical data.
To support increased adoption, the elluminate platform currently includes over 20 out-of-the-box connectors for enterprise interoperability with different software providers and is expanding these capabilities. Recent growth in the elluminate partner network includes AG Mednet and Clinical Ink. “These partners allow for the seamless flow of more data sources into elluminate for ease of use and expansion of the elluminate ecosystem. We’re proud to work with life science leaders in technology, systems integrators, CROs and consulting who share our goal of improving clinical development through faster, data-driven processes,” said Bob Arnesen, eClinical Solutions President and Co-Founder.
eClinical has also made several key additions to its senior leadership team in recent months to drive critical business functions and strategies and is continuing to increase its footprint in Europe, adding operations in Germany. It is also expanding its links with industry associations including MassBio, California Life Sciences Association and Biocom to spark innovation in life sciences.
“Now is the time to solve the data problem in life sciences,” said Raj Indupuri, Co-Founder and CEO of eClinical Solutions. “The process of reviewing, standardising and analysing clinical data has not changed substantially in 25 years. With technology platforms like elluminate, we can build on the industry-wide advances made during the pandemic, help manage the data streams coming from decentralised trials and deliver new and important treatments faster to the patients who await them.”